Hi The journey to bring a new mental health treatment to market is a rigorous one, but the potential of MindBio Therapeutics’ lead candidate, MB22001, makes it all worthwhile. We’re thrilled to share that MB22001 is showing exceptional promise in add...

Hi Last month, I launched app.booze-ai.com in Silicon Valley. I was anxious, to be honest, pitching to VCs amongst some of the sharpest MIT, Harvard and Stanford AI engineers in the world.I need not have worried as the presentation was received well...

Hi Last week, MindBio enrolled the final patient in its landmark Phase 2B trial,trial testing MB22001 in patients with Major Depressive Disorder.READ MOREEven I have been surprised by the data from our trials as we slowly progress the drug to the nex...

Hi It's a marathon of clinical trials to get a new medicine approved and its worth it if MindBio's lead candidate MB22001 can prove more effective and without the side effects seen commonly in anti-depressant medications.To date, the trial outcomes h...

Hi MindBio Therapeutics (CNSX: MBIO) launches Booze AI to Investors in Silicon Valley.The World's First Voice Activated & AI Powered Blood Alcohol Estimator over a Smartphone goes Live.It was a surprising discovery with speech analysis in our cli...

Dr Rachael Sumner discusses Microdosing MB22001 for negative mood symptom relief in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Here is the link to the clinical trial paper on Sleep produced by MindBio scientific collaborators and published in Nature’s portfolio journal Translational Psychiatry:https://www.nature.com/articles/s41398-024-02900-4

Unlocking Market Potential: Leveraging Big Data Analytics to Revolutionize Depression Research

MindBio publishes positive Phase 2a Data in Landmark Depression Trial

Positive Phase 2a results reported in Depression trial. Permalink